Multiregional analysis of combined hepatocellular-cholangiocarcinoma reveals histologic diversity and molecular clonality

被引:3
|
作者
Na, Hee Young [1 ]
Kim, Jee Hyun [2 ]
Kim, Haeryoung [3 ]
Cho, Jai Young [4 ]
Han, Ho-Seong [4 ]
Jang, Eun Sun [5 ]
Kim, Jin-Wook [5 ]
Jeong, Sook-Hyang [5 ]
Heo, Jayoon [2 ,6 ]
Kim, Ji-Won [2 ]
Kim, Jin Won [2 ]
Ahn, Soomin [1 ,7 ,8 ]
机构
[1] Seoul Natl Univ, Bundang Hosp, Dept Pathol, Coll Med, Seongnam, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Internal Med, Div Hematol & Med Oncol,Bundang Hosp, Seongnam, South Korea
[3] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul Natl Univ Hosp, Seoul, South Korea
[4] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Surg, Seongnam, South Korea
[5] Seoul Natl Univ, Coll Med, Dept Internal Med, Div Gastroenterol,Bundang Hosp, Seongnam, South Korea
[6] Ilsan Hosp, Dept Internal Med, Natl Hlth Insurance Serv, Goyang, South Korea
[7] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol & Translat Genom, Seoul, South Korea
[8] Sungkyunkwan Univ, Samsung Med Ctr, Dept Pathol & Translat Genom, Sch Med, 81 Irwon ro, Seoul 06351, South Korea
关键词
combined hepatocellular-cholangiocarcinoma; intermediate cell carcinoma; liver; next-generation sequencing; CARCINOMA;
D O I
10.1111/his.15081
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare type of liver tumour that exhibits both hepatocytic and biliary differentiation within the same tumour. The histology and genomic alterations of recurrent/metastatic cHCC-CC are poorly understood. We selected six patients with cHCC-CC whose recurrent or metastatic tumours were histologically confirmed. Four patients with classic cHCC-CCs and two with intermediate cell carcinomas (ICs) were included. The clinicopathological features were evaluated, and next-generation sequencing was performed in 17 multiregional and longitudinal tumour samples. The histology of recurrent/metastatic lesions of classic cHCC-CCs was variable: hepatocellular carcinoma (HCC) was observed in one (25.0%) patient, cHCC-CC in one (25.0%) patient, and cholangiocarcinoma (CC) in two (50.0%) patients. Among 13 samples from four classic cHCC-CC patients, the most frequent pathological variants were TP53 (46.2%), TERT promoter (38.5%), ARID1A mutations (23.1%), and MET amplification (30.8%). In the sequencing analysis of each HCC and CC component, three (75.0%) of the four classic cHCC-CCs shared pathogenic variants. A large proportion of mutations, both pathogenic and those of undetermined significance, were shared by each HCC and CC component. Regarding ICs, the ATM mutation was detected in one patient. In conclusion, the histology of recurrent/metastatic cHCC-CCs was heterogeneous. Genomic profiling of classic cHCC-CCs revealed similar genomic alterations to those of HCC. Considerable overlapping genomic alterations in each HCC and CC component were observed, suggesting a monoclonal origin. Genetic alterations in ICs were different from those in either HCC or CC, suggesting the distinct nature of this tumour. The histology of recurrent/metastatic tumours of cHCC-CCs was variable. Genomic profiling of cHCC-CC revealed considerable overlapping genomic alterations in each HCC and CC component.image
引用
收藏
页码:402 / 408
页数:7
相关论文
共 50 条
  • [21] MRI features of combined hepatocellular-cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma
    Sammon, Jennifer
    Fischer, Sandra
    Menezes, Ravi
    Hosseini-Nik, Hooman
    Lewis, Sara
    Taouli, Bachir
    Jhaveri, Kartik
    CANCER IMAGING, 2018, 18
  • [22] Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma
    Zhao, Linghao
    Wang, Yuyouye
    Tian, Tao
    Rao, Xinjie
    Dong, Wei
    Zhang, Jinmin
    Yang, Yuan
    Tao, Qifei
    Peng, Fang
    Shen, Chenhang
    Wang, Songbo
    Liu, Hui
    Zeng, Xi
    Zhou, Weiping
    HEPATOLOGY INTERNATIONAL, 2022, 16 (06) : 1339 - 1352
  • [23] Breast Metastasis From a Combined Hepatocellular-Cholangiocarcinoma
    Silva, Marco
    Coelho, Rosa
    Rios, Elisabete
    Gomes, Sara
    Carneiro, Fatima
    Macedo, Guilherme
    ACG CASE REPORTS JOURNAL, 2019, 6 (04)
  • [24] Combined hepatocellular-cholangiocarcinoma: biology, diagnosis, and management
    Ye, Liangtao
    Schneider, Julia S. S.
    Ben Khaled, Najib
    Schirmacher, Peter
    Seifert, Carolin
    Frey, Lea
    He, Yulong
    Geier, Andreas
    De Toni, Enrico N. N.
    Zhang, Changhua
    Reiter, Florian P. P.
    LIVER CANCER, 2024, 13 (01) : 6 - 28
  • [25] A Novel Risk prediction Model for Patients with Combined Hepatocellular-Cholangiocarcinoma
    Tian, Meng-Xin
    He, Wen-Jun
    Liu, Wei-Ren
    Yin, Jia-Cheng
    Jin, Lei
    Tang, Zheng
    Jiang, Xi-Fei
    Wang, Han
    Zhou, Pei-Yun
    Tao, Chen-Yang
    Ding, Zhen-Bin
    Peng, Yuan-Fei
    Dai, Zhi
    Qiu, Shuang-Jian
    Zhou, Jian
    Fan, Jia
    Shi, Ying-Hong
    JOURNAL OF CANCER, 2018, 9 (06): : 1025 - 1032
  • [26] Recurrence patterns of combined hepatocellular-cholangiocarcinoma on enhanced computed tomography
    Shin, Cheong-Il
    Lee, Jeong Min
    Kim, Se Hyung
    Choi, Jin Young
    Lee, Jae Young
    Han, Joon Koo
    Jo, Soo Yeon
    Choi, Byung Ihn
    JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 2007, 31 (01) : 109 - 115
  • [27] Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma
    Linghao Zhao
    Yuyouye Wang
    Tao Tian
    Xinjie Rao
    Wei Dong
    Jinmin Zhang
    Yuan Yang
    Qifei Tao
    Fang Peng
    Chenhang Shen
    Songbo Wang
    Hui Liu
    Xi Zeng
    Weiping Zhou
    Hepatology International, 2022, 16 : 1339 - 1352
  • [28] Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma
    Satake, Tomoyuki
    Shibuki, Taro
    Watanabe, Kazuo
    Sasaki, Mitsuhito
    Imaoka, Hiroshi
    Mitsunaga, Shuichi
    Kojima, Motohiro
    Ikeda, Masafumi
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [29] Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma
    Chan, Lauren S.
    Sze, Daniel Y.
    Poultsides, George A.
    Louie, John D.
    Mohammed, Mohammed A. Abdelrazek
    Wang, David S.
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2017, 40 (09) : 1383 - 1391
  • [30] Sarcomatoid combined hepatocellular-cholangiocarcinoma: a case report and review of literature
    Chin, Susie
    Kim, Zisun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (11): : 8290 - 8294